Companies /Healthcare

Zentalis Pharmaceuticals Inc

NASDAQ: ZNTL Biotechnology
$1.49
▼ $0.11 (−6.88%) today
Markets closed · 4:03am ET

ZNTL at a Glance

Valuation
Market cap
$157.2M
Profitability
Revenue (TTM)
$26.9M
EPS (TTM)
$-1.90
Price
52-week range
$1 – $7
Street target
$7.44

Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ZNTL zentalis.com

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a clinical-stage oncology company with no product revenue. Its development is focused on azenosertib (ZN-c3), an investigational, orally bioavailable, selective WEE1 kinase inhibitor.

The lead indication is Cyclin E1-positive platinum-resistant ovarian cancer (PROC), a biomarker-selected group making up about 50% of PROC patients. These patients have no specifically targeted approved therapy. The company uses a proprietary Cyclin E1 immunohistochemistry (IHC) assay and is pursuing companion diagnostic registration.

Clinical programs:
- DENALI: a registration-intended Phase 2 trial with FDA Fast Track Designation, aimed at potential accelerated approval.
- ASPENOVA: a randomized, confirmatory Phase 3 trial of about 420 patients comparing azenosertib with standard-of-care chemotherapy, designed for full approval in the U.S. and major ex-U.S. markets.
- MUIR: a Phase 1b study combining azenosertib with bevacizumab as maintenance therapy in platinum-sensitive ovarian cancer.
- A planned combination study in triple-negative breast cancer, including potential pairings with antibody-drug conjugates (ADCs).

More than 1,000 patients have been treated with azenosertib across tumor types. Zentalis is funded through equity offerings, including an August 2026 follow-on offering. Updated

ZNTL Coverage

Frequently Asked Questions

What does Zentalis Pharmaceuticals do?

Zentalis Pharmaceuticals is a clinical-stage oncology company with no product revenue. Its development is focused on azenosertib (ZN-c3), an investigational, orally bioavailable, selective WEE1 kinase inhibitor.

What is the ZNTL stock price target?

The Wall Street consensus 12-month price target for ZNTL is $7.44.